|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2003-1-14
|
|
pubmed:abstractText |
To determine the maximum tolerated dose and pharmacokinetics of cantuzumab mertansine, an immunoconjugate of the potent maytansine derivative (DM1) and the humanized monoclonal antibody (huC242) directed to CanAg, intravenously (i.v.) once every 3 weeks and to seek evidence of antitumor activity.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:AudetteCharleneC,
pubmed-author:ChariRavi V JRV,
pubmed-author:DeWitteMarkM,
pubmed-author:EdwardsTamT,
pubmed-author:HammondLisa ALA,
pubmed-author:JohnsonRandallR,
pubmed-author:JonakZdenka LZL,
pubmed-author:LambertJohn MJM,
pubmed-author:MaesKateK,
pubmed-author:MartinoHelenH,
pubmed-author:MaysTheresaT,
pubmed-author:OchoaLeonelL,
pubmed-author:PatnaikAmitaA,
pubmed-author:RowinskyEric KEK,
pubmed-author:SchwartzGarryG,
pubmed-author:SmithLonL,
pubmed-author:TakimotoChrisC,
pubmed-author:TolcherAnthony WAW,
pubmed-author:de BonoJohannJ
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
211-22
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:12525512-Adult,
pubmed-meshheading:12525512-Aged,
pubmed-meshheading:12525512-Antibodies, Monoclonal,
pubmed-meshheading:12525512-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:12525512-Dose-Response Relationship, Drug,
pubmed-meshheading:12525512-Female,
pubmed-meshheading:12525512-Half-Life,
pubmed-meshheading:12525512-Humans,
pubmed-meshheading:12525512-Immunoconjugates,
pubmed-meshheading:12525512-Infusions, Intravenous,
pubmed-meshheading:12525512-Male,
pubmed-meshheading:12525512-Maximum Tolerated Dose,
pubmed-meshheading:12525512-Maytansine,
pubmed-meshheading:12525512-Middle Aged,
pubmed-meshheading:12525512-Mucin-1,
pubmed-meshheading:12525512-Neoplasms
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
|
|
pubmed:affiliation |
Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, TX 78229, USA. atolcher@saci.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase I
|
